NCT06500741

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 374 (actual)
• Sponsor: Astellas Pharma Global Development, Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).

Detailed description

The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
OTHER	No Intervention	No investigational drug will be administered to participants in this study.

Timeline

• Start date: 2024-11-22
• Primary completion: 2025-04-02
• Completion: 2025-04-02
• First posted: 2024-07-15
• Last updated: 2025-05-06

Locations

1 site across 1 country: United States